Across TCGA pan-cancer cohorts, AFG3L1P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AFG3L1P data layer compared with 24 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher AFG3L1P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated AFG3L1P expression acts as an unfavorable survival marker.

CESC are the cancer types where AFG3L1P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.241	0.740	.029	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: AFG3L1P tumor-vs-normal RNA expression · all AFG3L1P data types